Christopher Benz

Summary

Affiliation: Buck Institute for Age Research
Country: USA

Publications

  1. pmc Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?
    Anguraj Sadanandam
    Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
    Breast Cancer Res Treat 136:693-703. 2012
  2. pmc A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer
    Christina Yau
    Buck Institute for Age Research, Novato, CA 94945, USA
    Breast Cancer Res 12:R85. 2010
  3. doi request reprint Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305
    Jason M Held
    Buck Institute for Research on Aging, Novato, CA 94945, USA
    Mol Cancer Res 10:1120-32. 2012
  4. pmc Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies
    Michael D Mattie
    UCSF Comprehensive Cancer Center, Department of Urology, San Francisco, California 94115, USA
    Mol Cancer 5:24. 2006
  5. pmc Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome
    Vincent Vuaroqueaux
    Stiftung Tumorbank Basel, Lörracherstrasse 50, 4125 Riehen, Switzerland
    Breast Cancer Res 9:R33. 2007
  6. pmc Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers
    Christina Yau
    Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
    Breast Cancer Res 9:R59. 2007
  7. pmc Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers
    Christina Yau
    Buck Institute for Age Research, Redwood Boulevard, Novato, California 94945, USA
    Breast Cancer Res 10:R61. 2008
  8. pmc Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California
    Rochelle R Ereman
    County of Marin, Department of Health and Human Services, 20 North San Pedro Road, San Rafael, CA 94903, USA
    BMC Public Health 10:228. 2010
  9. pmc Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer
    Yamei Zhou
    Buck Institute for Age Research, Novato, CA 94945, USA
    BMC Cancer 7:59. 2007
  10. ncbi request reprint Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers
    Christopher C Benz
    Buck Institute for Age Research, Novato, CA 94945, USA
    Genes Chromosomes Cancer 45:983-94. 2006

Research Grants

Collaborators

Detail Information

Publications48

  1. pmc Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?
    Anguraj Sadanandam
    Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
    Breast Cancer Res Treat 136:693-703. 2012
    ....
  2. pmc A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer
    Christina Yau
    Buck Institute for Age Research, Novato, CA 94945, USA
    Breast Cancer Res 12:R85. 2010
    ....
  3. doi request reprint Ligand binding promotes CDK-dependent phosphorylation of ER-alpha on hinge serine 294 but inhibits ligand-independent phosphorylation of serine 305
    Jason M Held
    Buck Institute for Research on Aging, Novato, CA 94945, USA
    Mol Cancer Res 10:1120-32. 2012
    ....
  4. pmc Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies
    Michael D Mattie
    UCSF Comprehensive Cancer Center, Department of Urology, San Francisco, California 94115, USA
    Mol Cancer 5:24. 2006
    ..Here we describe a novel combination of linear amplification and labeling of miRNA for highly sensitive expression microarray profiling requiring only picogram quantities of purified microRNA...
  5. pmc Low E2F1 transcript levels are a strong determinant of favorable breast cancer outcome
    Vincent Vuaroqueaux
    Stiftung Tumorbank Basel, Lörracherstrasse 50, 4125 Riehen, Switzerland
    Breast Cancer Res 9:R33. 2007
    ..We investigated whether mRNA levels of E2F1, a key transcription factor involved in proliferation, differentiation and apoptosis, could be used as a surrogate marker for the determination of breast cancer outcome...
  6. pmc Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers
    Christina Yau
    Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
    Breast Cancer Res 9:R59. 2007
    ..Except for inherited forms of breast cancer, however, there is little genetic or epigenetic understanding of the biological basis linking aging with sporadic breast cancer incidence and its clinical behavior...
  7. pmc Genes responsive to both oxidant stress and loss of estrogen receptor function identify a poor prognosis group of estrogen receptor positive primary breast cancers
    Christina Yau
    Buck Institute for Age Research, Redwood Boulevard, Novato, California 94945, USA
    Breast Cancer Res 10:R61. 2008
    ..Oxidative stress can modify estrogen receptor (ER) structure and function, including induction of progesterone receptor (PR), altering the biology and clinical behavior of endocrine responsive (ER-positive) breast cancer...
  8. pmc Recent trends in hormone therapy utilization and breast cancer incidence rates in the high incidence population of Marin County, California
    Rochelle R Ereman
    County of Marin, Department of Health and Human Services, 20 North San Pedro Road, San Rafael, CA 94903, USA
    BMC Public Health 10:228. 2010
    ....
  9. pmc Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer
    Yamei Zhou
    Buck Institute for Age Research, Novato, CA 94945, USA
    BMC Cancer 7:59. 2007
    ..Signaling pathways that converge on two different transcription factor complexes, NFkappaB and AP-1, have been identified in estrogen receptor (ER)-positive breast cancers resistant to the antiestrogen, tamoxifen...
  10. ncbi request reprint Altered promoter usage characterizes monoallelic transcription arising with ERBB2 amplification in human breast cancers
    Christopher C Benz
    Buck Institute for Age Research, Novato, CA 94945, USA
    Genes Chromosomes Cancer 45:983-94. 2006
    ....
  11. pmc Impact of aging on the biology of breast cancer
    Christopher C Benz
    Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
    Crit Rev Oncol Hematol 66:65-74. 2008
    ..g. estrogen receptor, ER) and growth factor receptor (e.g. HER2) expression, supporting the conclusion that the biology of breast cancer is age-dependent...
  12. ncbi request reprint Geographic excess of estrogen receptor-positive breast cancer
    Christopher C Benz
    Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, Novato, California 94945, USA
    Cancer Epidemiol Biomarkers Prev 12:1523-7. 2003
    ..The progressive increase in breast cancer incidence rates observed in Marin County over the past decade is occurring in women with high prevalence of risk factors predisposing toward excess development of ER+/PR+ breast cancer...
  13. ncbi request reprint Novel pathways associated with quinone-induced stress in breast cancer cells
    Christopher C Benz
    Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, Novato, CA 94945, USA
    Drug Metab Rev 38:601-13. 2006
    ....
  14. ncbi request reprint Transcriptional repression of ErbB2 by histone deacetylase inhibitors detected by a genomically integrated ErbB2 promoter-reporting cell screen
    Gary K Scott
    Program of Cancer and Development Therapeutics, Buck Institute for Age Research, Novato, California 94945, USA
    Mol Cancer Ther 1:385-92. 2002
    ..These findings suggest that further studies are warranted to determine whether ErbB2-positive human cancers represent unusually sensitive clinical targets for HDAC inhibitor therapy...
  15. ncbi request reprint Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, Buck Institute for Age Research, Novato, California 94945, USA
    Clin Cancer Res 11:3392-401. 2005
    ....
  16. ncbi request reprint Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b
    Gary K Scott
    Buck Institute for Age Research, Novato, California 94945, USA
    J Biol Chem 282:1479-86. 2007
    ..These results illustrate the feasibility of using miRNAs as a therapeutic strategy to suppress oncogene expression and function...
  17. pmc Destabilization of ERBB2 transcripts by targeting 3' untranslated region messenger RNA associated HuR and histone deacetylase-6
    Gary K Scott
    Buck Institute for Age Research, Novato, CA 94945, USA
    Mol Cancer Res 6:1250-8. 2008
    ....
  18. ncbi request reprint Rapid alteration of microRNA levels by histone deacetylase inhibition
    Gary K Scott
    Program of Cancer and Developmental Therapeutics, Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
    Cancer Res 66:1277-81. 2006
    ..These findings emphasize the importance of post-transcriptional mRNA regulation by HDACi in addition to their established effects on promoter-driven gene expression...
  19. ncbi request reprint Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers
    Yamei Zhou
    Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd, Novato, CA 94945, USA
    Int J Biochem Cell Biol 37:1130-44. 2005
    ....
  20. ncbi request reprint Validated high-throughput screening of drug-like small molecules for inhibitors of ErbB2 transcription
    Corina Marx
    Program of Cancer and Development Therapeutics, Buck Institute for Age Research, Novato, CA 94945, USA
    Assay Drug Dev Technol 4:273-84. 2006
    ....
  21. ncbi request reprint Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer
    Corina Marx
    Cancer and Developmental Therapeutics Program, Buck Institute for Age Research, 8001 Redwood Blvd, Novato, CA 94945, USA
    Mol Pharmacol 71:1525-34. 2007
    ....
  22. ncbi request reprint ErbB2 activation of ESX gene expression
    Richard M Neve
    Buck Institute for Age Research, 8001 Redwood Boulevard, Novato, CA 94945, USA
    Oncogene 21:3934-8. 2002
    ..These results indicate that the ESX promoter represents a transcriptional target of ErbB2, and ESX expression may represent a downstream mediator of ErbB2 signaling and ErbB2-induced gene expression...
  23. ncbi request reprint Consensus statement: Expedition Inspiration fund for breast cancer research meeting 2002
    Christopher Benz
    Buck Institute, Novato, CA, USA
    Breast Cancer Res Treat 78:127-31. 2003
  24. ncbi request reprint Essential cysteine-alkylation strategies to monitor structurally altered estrogen receptor as found in oxidant-stressed breast cancers
    Jose E Meza
    Buck Institute for Age Research Program of Cancer and Developmental Therapeutics, Novato, CA 94945, USA
    Anal Biochem 320:21-31. 2003
    ..These improved analytical strategies should facilitate the monitoring of structurally altered endogenous ER produced within oxidant-stressed human breast cancer cells...
  25. ncbi request reprint Vitamin K3 (menadione)-induced oncosis associated with keratin 8 phosphorylation and histone H3 arylation
    Gary K Scott
    Program of Cancer and Developmental Therapeutics, Buck Institute for Age Research, 8001 Red wood Blvd, Novato, CA 94945, USA
    Mol Pharmacol 68:606-15. 2005
    ..These findings delineate new pathways associated with K3-induced stress and suggest a potentially novel role for H3 Cys110 as a nuclear stress sensor...
  26. pmc ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination
    Corina Marx
    Buck Institute for Age Research, Novato, California 94945, USA
    Cancer Res 70:3709-17. 2010
    ....
  27. pmc Ageing, oxidative stress and cancer: paradigms in parallax
    Christopher C Benz
    Christopher C Benz and Christina Yau are at the Buck Institute for Age Research, Novato, California 94945, USA
    Nat Rev Cancer 8:875-9. 2008
    ..of gene expression in age-controlled breast cancer cases indicate that this deduction is false, posing parallax views of these two paradigms, and highlighting the unanswered question: does ageing cause or simply permit cancer development?..
  28. pmc Systematic mapping of posttranslational modifications in human estrogen receptor-alpha with emphasis on novel phosphorylation sites
    Christian Atsriku
    Buck Institute for Age Research, Novato, California 94945, USA
    Mol Cell Proteomics 8:467-80. 2009
    ....
  29. ncbi request reprint Meeting report: Translational Research at the Aging and Cancer Interface
    Christopher C Benz
    Buck Institute for Age Research, Novato, California, USA
    Cancer Res 67:4560-3. 2007
  30. doi request reprint A novel serine phosphorylation site detected in the N-terminal domain of estrogen receptor isolated from human breast cancer cells
    David J Britton
    Buck Institute for Age Research, Novato, California 94945, USA
    J Am Soc Mass Spectrom 19:729-40. 2008
    ....
  31. ncbi request reprint Age-associated biomarker profiles of human breast cancer
    Serenella Eppenberger-Castori
    Stiftung Tumorbank Basel and Department of Research, University Clinics, Basel, Switzerland
    Int J Biochem Cell Biol 34:1318-30. 2002
    ..In particular, breast tumors arising in older patients have slower growth rates, are more likely to be ER-positive, and are less likely to be p53-positive, EGFR-positive or ErbB2-positive...
  32. ncbi request reprint Age-dependent changes in breast cancer hormone receptors and oxidant stress markers
    Judy Quong
    Comprehensive Cancer Center, University of California, San Francisco, CA, USA
    Breast Cancer Res Treat 76:221-36. 2002
    ....
  33. ncbi request reprint 655Val and 1170Pro ERBB2 SNPs in familial breast cancer risk and BRCA1 alterations
    Stefania Tommasi
    National Cancer Institute Bari, Italy
    Cell Oncol 29:241-8. 2007
    ..In conclusion, these findings point to the existence of an association of ERBB2 allelic variants at both loci with specific breast tumor phenotypes and to the need of deeply investigate different gene SNPs association for risk defining...
  34. ncbi request reprint Risk factors for estrogen receptor-positive breast cancer
    E Shelley Hwang
    Department of Surgery, University of California, San Francisco, Cancer Center, 94115, USA
    Arch Surg 140:58-62. 2005
    ..Some risk factors associated with breast cancer may be more predictive of estrogen receptor (ER)- positive than ER-negative tumors...
  35. ncbi request reprint Breast cancer growth prevention by statins
    Michael J Campbell
    Department of Surgery, University of California San Francisco Mt Zion Medical Center, Room C342, 1600 Divisadero, San Francisco, CA 94115, USA
    Cancer Res 66:8707-14. 2006
    ..These findings provide supporting rationale for future statin trials in breast cancer patients...
  36. ncbi request reprint Identification of an epithelial-specific enhancer regulating ESX expression
    Richard M Neve
    Cancer Research Institute, University of California San Francisco, Box 0808, San Francisco, CA 94143 0808, USA
    Gene 367:118-25. 2006
    ..Understanding the regulation of this element will lend insight into mechanisms of epithelial differentiation and the etiology of breast cancer and may provide novel targets for cancer therapeutic intervention...
  37. doi request reprint Estrogen receptor-negative breast cancer is less likely to arise among lipophilic statin users
    Anjali S Kumar
    Department of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, California, USA
    Cancer Epidemiol Biomarkers Prev 17:1028-33. 2008
    ....
  38. ncbi request reprint Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis
    Ulrik B Nielsen
    Department of Anesthesia and Pharmaceutical Chemistry, University of California San Francisco, SF General Hospital, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    Biochim Biophys Acta 1591:109-118. 2002
    ..This strategy should be applicable to generate immunotherapeutics for other malignancies by selecting phage antibodies for internalization into other tumor types and using the scFv to target liposomes or other nanoparticles...
  39. ncbi request reprint Redox control of zinc finger proteins
    Michael A Baldwin
    Mass Spectrometry Facility, Department of Pharmaceutical Chemistry, University of California, San Francisco, California 94143, USA
    Methods Enzymol 353:54-69. 2002
  40. ncbi request reprint Clinical trials are required to prove the chemopreventive worth of statins
    Anjali S Kumar
    Arch Intern Med 166:1143; author reply 1144. 2006
  41. ncbi request reprint Future directions of liposome- and immunoliposome-based cancer therapeutics
    John W Park
    UCSF Comprehensive Cancer Center, San Francisco, CA 94115 1710, USA
    Semin Oncol 31:196-205. 2004
    ....
  42. ncbi request reprint Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery
    John W Park
    Division of Hematology Oncology, University of California, San Francisco, San Francisco, California 94143, USA
    Clin Cancer Res 8:1172-81. 2002
    ..We previously showed that anti-HER2 immunoliposomes bind efficiently to and internalize in HER2-overexpressing cells in vitro, resulting in intracellular drug delivery...
  43. ncbi request reprint Clinical development of histone deacetylase inhibitors as anticancer agents
    Daryl C Drummond
    Hermes Biosciences, Inc, South San Francisco, California 94080, USA
    Annu Rev Pharmacol Toxicol 45:495-528. 2005
    ....
  44. ncbi request reprint Hyperplasia, reduced E-cadherin expression, and developmental arrest in mammary glands oxidatively stressed by loss of mitochondrial superoxide dismutase
    Hema Parmar
    Department of Anatomy, University of California, San Francisco, CA 94143, USA
    Breast 14:256-63. 2005
    ..These findings suggest that excess oxidative stress from loss of SOD2 function can arrest mammary gland maturation and induce hyperplastic epithelium with early premalignant features...
  45. ncbi request reprint Type and duration of exogenous hormone use affects breast cancer histology
    Anjali S Kumar
    Department of Surgery, Kaiser Permanente Oakland Medical Center, Oakland, California, 94602, USA
    Ann Surg Oncol 14:695-703. 2007
    ..We conducted this investigation to assess whether the type of hormone used (none, estrogen, progesterone, or combined) and duration of use influences subsequent breast cancer histology...
  46. ncbi request reprint A call for clinical trials: lipophilic statins may prove effective in treatment and prevention of particular breast cancer subtypes
    Anjali S Kumar
    J Clin Oncol 24:2127; author reply 2127-8. 2006
  47. ncbi request reprint Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models
    Dmitri B Kirpotin
    Hermes Biosciences Inc, South San Francisco, CA, USA
    Cancer Res 66:6732-40. 2006
    ..Immunoliposomes capable of selective internalization in cancer cells in vivo may provide new opportunities for drug delivery...
  48. ncbi request reprint Anti-CD166 single chain antibody-mediated intracellular delivery of liposomal drugs to prostate cancer cells
    Audrey Roth
    Department of Anesthesia, University of California at San Francisco, Room 3C38, 1001 Potrero Avenue, San Francisco, CA 94110, USA
    Mol Cancer Ther 6:2737-46. 2007
    ..Further studies on intracellular tracking of endocytosed liposomal drugs will help identify and overcome the barriers limiting the potency of liposomal drugs...

Research Grants24

  1. THERAPEUTIC MODULATION OF BREAST CANCER ONCOGENES
    Christopher Benz; Fiscal Year: 2006
    ..abstract_text> ..
  2. THERAPEUTIC MODULATION OF BREAST CANCER ONCOGENES
    Christopher Benz; Fiscal Year: 2007
    ..tumor-targeted uptake of selected candidates by encapsulation into anti-ErbB2 immunoliposomes (ILs), and these ErbB2 receptor- and promoter-targeted ILs agents will be evaluated in vivo for further clinical development ..
  3. DEFECTIVE ESTROGEN RECEPTORS IN BREAST TUMORS
    Christopher Benz; Fiscal Year: 2007
    ..Together, these aims will relate oxidant stress responses with specific oxER-associated mechanistic pathways, and validate the clinical significance of measuring oxER-associated parameters in human breast tumors. ..
  4. Biology of Breast Cancers Arising in Older Women
    Christopher Benz; Fiscal Year: 2007
    ..abstract_text> ..
  5. THERAPEUTIC MODULATION OF BREAST CANCER ONCOGENES
    Christopher Benz; Fiscal Year: 2002
    ....
  6. THERAPEUTIC MODULATION OF BREAST CANCER ONCOGENES
    Christopher Benz; Fiscal Year: 2003
    ..abstract_text> ..
  7. Mass spectrometry to decode PTM patterns and enhance the Biomarker utility of ER
    Christopher Benz; Fiscal Year: 2010
    ....